Pfizer to supply US with additional 100 million doses of Covid-19 vaccine

Pfizer vaccine

Pfizer and BioNTech will supply the US with an additional 100 million doses of the COVID-19 vaccine under a new agreement.

The drugmakers said Wednesday that they expect to deliver all the doses by July 31.

Pfizer already has a contract to supply the government with 100 million doses of its vaccine.

Pfizer's vaccine was the first to gain approval from the Food and Drug Administration and initial shipments went to states last week. It has now been joined by a vaccine from Moderna, which was developed in closer cooperation with scientists from the National Institutes of Health.

Moderna's vaccine comes under the umbrella of the government's own effort, which is called Operation Warp Speed. That public-private endeavor was designed to have millions of vaccine doses ready and available to ship once a shot received FDA approval.

The deal with Pfizer moves the nation closer to the goal of vaccinating all Americans.

A law dating back to the Korean War gives the government authority to direct private companies to produce critical goods in times of national emergency. Called the Defence Production Act, its expected to be invoked to help Pfizer secure some raw materials needed for its vaccine.

Pfizer already had a contract to supply the government with 100 million doses of its vaccine under Operation Warp Speed, but government officials have said its more of an arms-length relationship with the company and they dont have as much visibility into its operations.

Health and Human Services Secretary Alex Azar said last week that the government was negotiating with Pfizer for more doses, but details provided on Tuesday about the company's desire for better access to supplies are new.

"With these 100 million additional doses, the United States will be able to protect more individuals and hopefully end this devastating pandemic more quickly," said Pfizer CEO Albert Bourla. We look forward to continuing our work with the US government and healthcare providers around the country.

The vaccine from Pfizer and German pharmaceutical BioNTech immediately raised hopes of taming a pandemic that has killed nearly 320,000 people in the US and hobbled much of the national economy.

Health care workers and nursing home residents topped the list as local TV stations across the country began broadcasting scenes of the first vaccinations. Some polls show skepticism about getting vaccinated may be easing.

After early failures with testing, Trump administration officials are hoping to write a very different ending with vaccines. Operation Warp Speed has financed the development, manufacture and distribution of millions of doses, with the goal of providing a free vaccine to any American who wants one.

Operation Warp Speed is on track to have about 40 million doses of vaccine by the end of this month, of which about 20 million would be allocated for first vaccinations. Distribution of those doses would span into the first week of January. Both the Pfizer and Moderna vaccines require two shots to be fully effective.

The New York Times first reported the new details of negotiations between Pfizer and the Trump administration.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel